A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.
Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.
A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.
One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
Cytochromes of the b group that have alpha-band absorption of 563-564 nm. They occur as subunits in MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III.
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585)
A genus of ascomycetous FUNGI, family Pneumocystidaceae, order Pneumocystidales. It includes various host-specific species causing PNEUMOCYSTIS PNEUMONIA in humans and other MAMMALS.
Antioxidant for foods, fats, oils, ethers, emulsions, waxes, and transformer oils.
Tests that demonstrate the relative effectiveness of chemotherapeutic agents against specific parasites.
A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.
Colloids with liquid continuous phase and solid dispersed phase; the term is used loosely also for solid-in-gas (AEROSOLS) and other colloidal systems; water-insoluble drugs may be given as suspensions.
A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
This drug combination has proved to be an effective therapeutic agent with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.
Agents useful in the treatment or prevention of COCCIDIOSIS in man or animals.
Infections of the BRAIN caused by the protozoan TOXOPLASMA gondii that primarily arise in individuals with IMMUNOLOGIC DEFICIENCY SYNDROMES (see also AIDS-RELATED OPPORTUNISTIC INFECTIONS). The infection may involve the brain diffusely or form discrete abscesses. Clinical manifestations include SEIZURES, altered mentation, headache, focal neurologic deficits, and INTRACRANIAL HYPERTENSION. (From Joynt, Clinical Neurology, 1998, Ch27, pp41-3)
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.
A multisubunit enzyme complex that contains CYTOCHROME B GROUP; CYTOCHROME C1; and iron-sulfur centers. It catalyzes the oxidation of ubiquinol to UBIQUINONE, and transfers the electrons to CYTOCHROME C. In MITOCHONDRIA the redox reaction is coupled to the transport of PROTONS across the inner mitochondrial membrane.
A sulfone active against a wide range of bacteria but mainly employed for its actions against MYCOBACTERIUM LEPRAE. Its mechanism of action is probably similar to that of the SULFONAMIDES which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with PYRIMETHAMINE in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
An order of protozoa comprising heteroxenous tick-borne blood parasites. Representative genera include BABESIA, Dactylosoma, and THEILERIA.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
An electrochemical technique for measuring the current that flows in solution as a function of an applied voltage. The observed polarographic wave, resulting from the electrochemical response, depends on the way voltage is applied (linear sweep or differential pulse) and the type of electrode used. Usually a mercury drop electrode is used.

Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum. (1/172)

Recent evidence suggests that the malaria parasite Plasmodium falciparum utilizes a branched respiratory pathway including both a cytochrome chain and an alternative oxidase. This branched respiratory pathway model has been used as a basis for examining the mechanism of action of two antimalarial agents, atovaquone and proguanil. In polarographic assays, atovaquone immediately reduced the parasite oxygen consumption rate in a concentration-dependent manner. This is consistent with its previously described role as an inhibitor of the cytochrome bc1 complex. Atovaquone maximally inhibited the rate of P. falciparum oxygen consumption by 73% +/- 10%. At all atovaquone concentrations tested, the addition of the alternative oxidase inhibitor, salicylhydroxamic acid, resulted in a further decrease in the rate of parasite oxygen consumption. At the highest concentrations of atovaquone tested, the activities of salicylhydroxamic acid and atovaquone appear to overlap, suggesting that at these concentrations, atovaquone partially inhibits the alternative oxidase as well as the cytochrome chain. Drug interaction studies with atovaquone and salicylhydroxamic acid indicate atovaquone's activity against P. falciparum in vitro is potentiated by this alternative oxidase inhibitor, with a sum fractional inhibitory concentration of 0.6. Propyl gallate, another alternative oxidase inhibitor, also potentiated atovaquone's activity, with a sum fractional inhibitory concentration of 0.7. Proguanil, which potentiates atovaquone activity in vitro and in vivo, had a small effect on parasite oxygen consumption in polarographic assays when used alone or in the presence of atovaquone or salicylhydroxamic acid. This suggests that proguanil does not potentiate atovaquone by direct inhibition of either branch of the parasite respiratory chain.  (+info)

Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. (2/172)

This randomized, open-label clinical trial compared a fixed-dose combination of atovaquone and proguanil (n=55) with chloroquine (n=23) or a combination of chloroquine, sulfadoxine, and pyrimethamine (n=32) for treatment of acute falciparum malaria in the Philippines. Patients were hospitalized for 28 days to ensure medication compliance and prevent reinfection. Atovaquone-proguanil produced a significantly higher cure rate (100%) compared with that for chloroquine (30.4%; P<.0001) or chloroquine-sulfadoxine-pyrimethamine (87.5%; P<.05). Treatments did not differ significantly with respect to parasite clearance time (mean: 46.7 h for atovaquone-proguanil, 60.0 h for chloroquine, and 42.8 h for chloroquine-sulfadoxine-pyrimethamine) or fever clearance time (mean, 38.8, 46.8, and 34.5 h, respectively). Adverse events were typical of malaria symptoms; the most frequently reported events were vomiting (18% for atovaquone-proguanil, 17% for chloroquine, and 9% for chloroquine-sulfadoxine-pyrimethamine), abdominal pain (15%, 17%, and 3%, respectively), anorexia (11%, 13%, and 0%, respectively), and headache (6%, 17%, and 3%, respectively). Atovaquone-proguanil was well tolerated and more effective than chloroquine or chloroquine-sulfadoxine-pyrimethamine for treatment of multidrug-resistant falciparum malaria in the Philippines.  (+info)

Prophylactic activity of atovaquone against Plasmodium falciparum in humans. (3/172)

The prophylactic antimalarial activity of atovaquone was determined in a randomized, double-blind, placebo-controlled study of healthy volunteers who were challenged by the bite of Plasmodium falciparum-infected Anopheles stephensi. Subjects were randomly assigned to one of three groups: six received seven daily doses of 750 mg of atovaquone, starting the day before challenge; six received a single dose of 250 mg of atovaquone the day before challenge; and four received placebo. Polymerase chain reaction- and culture-confirmed parasitemia developed in all four placebo recipients, but in none of the drug recipients, indicating that either of the atovaquone regimens provides effective prophylaxis (P = 0.005). However, in low-dose recipients, the drug levels by day 6.5 were profoundly subtherapeutic, indicating that parasites were eliminated prior to the establishment of erythrocytic infection. Atovaquone thus protects non-immune subjects against mosquito-transmitted falciparum malaria, and has causal prophylactic activity.  (+info)

A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. (4/172)

Malaria poses a major health risk to people who are exposed to infection in malaria-endemic areas. A randomized, double-blind, placebo-controlled study was conducted to determine the efficacy and safety of Malarone (250 mg of atovaquone/100 mg of proguanil hydrochloride per tablet) for the chemoprophylaxis of Plasmodium falciparum malaria in Zambia. Adult volunteers received a three-day treatment course of Malarone to eliminate pre-existing parasitemia and were then immediately randomized to treatment with either one Malarone tablet daily (n = 136), or one placebo tablet daily (n = 138) for at least 10 weeks. Malaria blood smears were prepared on a weekly basis and a failure of chemoprophylaxis was defined as any subject who had a positive blood smear, or who withdrew from the study due to a treatment-related adverse event. The prophylaxis success rates in the Malarone and placebo groups were 98% and 63%, respectively (P < 0.001). The most commonly reported adverse events with at least a possible causal relationship to study medication were headache and abdominal pain, which occurred with a higher incidence in the placebo group. No subjects were withdrawn from the study due to a treatment-related adverse event. Thus, Malarone appears to have an excellent safety and efficacy profile for the chemoprophylaxis of P. falciparum infection.  (+info)

Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. (5/172)

The increasing frequency of therapeutic failures in falciparum malaria underscores the need for novel, rapidly effective antimalarial drugs or drug combinations. Atovaquone and proguanil are blood schizonticides that demonstrate synergistic activity against multi-drug-resistant Plasmodium falciparum in vitro. In an open-label, randomized, controlled clinical trial conducted in Thailand, adult patients with acute P. falciparum malaria were randomly assigned to treatment with atovaquone and proguanil/hydrochloride (1,000 mg and 400 mg, respectively, administered orally at 24-hr intervals for three doses) or mefloquine (750 mg administered orally, followed 6 hr later by an additional 500-mg dose). Efficacy was assessed by cure rate (the percentage of patients in whom parasitemia was eliminated and did not recur during 28 days of follow-up), parasite clearance time (PCT), and fever clearance time (FCT). Safety was assessed by sequential clinical and laboratory assessments for 28 days. Atovaquone/proguanil was significantly more effective than mefloquine (cure rate 100% [79 of 79] vs. 86% [68 of 79]; P < 0.002). The atovaquone/proguanil and mefloquine treatments did not differ with respect to PCT (mean = 65 hr versus 74 hr) or FCT (mean = 59 hr versus 51 hr). Adverse events were generally typical of malaria symptoms and each occurred in < 10% of the patients in either group, with the exception of increased vomiting found in the atovaquone/proguanil group. Transient elevations of liver enzyme levels occurred more frequently in patients treated with atovaquone/proguanil than with mefloquine, but the differences were not significant and values returned to normal by day 28 in most patients. The combination of atovaquone and proguanil was well tolerated and more effective than mefloquine in the treatment of acute uncomplicated multidrug-resistant falciparum malaria in Thailand.  (+info)

Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. (6/172)

The continuing spread of drug-resistant malaria emphasizes the need for new antimalarial drugs. Atovaquone is a broad-spectrum antiprotozoal drug with a novel mechanism of action, via inhibition of parasite mitochondrial electron transport, and a favorable safety profile. Early studies with atovaquone alone for treatment of malaria demonstrated good initial control of parasitemia but an unacceptable rate of recrudescent parasitemia. Parasites isolated during recrudescence after treatment with atovaquone alone were resistant to atovaquone in vitro. The combination of atovaquone and proguanil is synergistic in vitro, and clinical studies demonstrated enhanced efficacy of the combination compared to either drug alone for treatment of malaria. Malarone, a fixed-dose combination of 250 mg of atovaquone and 100 mg of proguanil hydrochloride, is available in many countries for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum. At the recommended dose (in adults, four tablets once a day for three days), the overall cure rate was > 98% in more than 500 patients with falciparum malaria. In four randomized, controlled clinical trials, treatment with atovaquone and proguanil hydrochloride was significantly more effective than mefloquine (Thailand), amodiaquine (Gabon), chloroquine (Peru and the Philippines) or chloroquine plus pyrimethamine/sulfadoxine (Philippines). In clinical trials where the comparator drug was highly effective, treatment with atovaquone and proguanil hydrochloride was equally effective. Parasites isolated during recrudescence after treatment with the combination of atovaquone and proguanil were not resistant to atovaquone in vitro. The most commonly reported adverse events in clinical trials (abdominal pain, anorexia, nausea, vomiting, diarrhea and coughing) occurred with similar frequency in patients treated with a comparator drug. Malarone is a safe and effective new agent for treatment of malaria.  (+info)

A mechanism for the synergistic antimalarial action of atovaquone and proguanil. (7/172)

A combination of atovaquone and proguanil has been found to be quite effective in treating malaria, with little evidence of the emergence of resistance when atovaquone was used as a single agent. We have examined possible mechanisms for the synergy between these two drugs. While proguanil by itself had no effect on electron transport or mitochondrial membrane potential (DeltaPsim), it significantly enhanced the ability of atovaquone to collapse DeltaPsim when used in combination. This enhancement was observed at pharmacologically achievable doses. Proguanil acted as a biguanide rather than as its metabolite cycloguanil (a parasite dihydrofolate reductase [DHFR] inhibitor) to enhance the atovaquone effect; another DHFR inhibitor, pyrimethamine, also had no enhancing effect. Proguanil-mediated enhancement was specific for atovaquone, since the effects of other mitochondrial electron transport inhibitors, such as myxothiazole and antimycin, were not altered by inclusion of proguanil. Surprisingly, proguanil did not enhance the ability of atovaquone to inhibit mitochondrial electron transport in malaria parasites. These results suggest that proguanil in its prodrug form acts in synergy with atovaquone by lowering the effective concentration at which atovaquone collapses DeltaPsim in malaria parasites. This could explain the paradoxical success of the atovaquone-proguanil combination even in regions where proguanil alone is ineffective due to resistance. The results also suggest that the atovaquone-proguanil combination may act as a site-specific uncoupler of parasite mitochondria in a selective manner.  (+info)

Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. (8/172)

To evaluate if atovaquone (ATQ) interacts pharmacokinetically with azithromycin (AZ) in human immunodeficiency virus-infected children, 10 subjects (ages, 4 to 13 years) were randomized in a crossover study to receive AZ (5 mg/kg/day) alone (ALONE) or AZ (5 mg/kg/day) and ATQ (30 mg/kg/day) simultaneously (SIM) prior to receiving AZ and ATQ staggered by 12 h. Despite a lack of significant difference in the mean AZ pharmacokinetic parameters, the steady-state values of AZ's area under the concentration-time curve from 0 to 24 h and maximum concentration in serum were consistently lower (n = 7 of 7) for the SIM regimen than they were for the ALONE regimen. A larger study will be required to determine if ATQ affects AZ pharmacokinetics and efficacy in a clinically significant manner.  (+info)

Atovaquone is an antiprotozoal medication that is used to treat certain types of parasitic infections, including malaria caused by Plasmodium falciparum and P. vivax. It is also used to treat babesiosis, a tick-borne infection caused by the parasite Babesia microti. Atovaquone works by inhibiting the growth and reproduction of the parasites in the body. It is usually taken orally in the form of tablets or capsules.

Naphthoquinones are a class of organic compounds that contain a naphthalene ring with a quinone group. They are commonly found in plants and have a wide range of biological activities, including antioxidant, anti-inflammatory, and anticancer properties. In the medical field, naphthoquinones are being studied for their potential use in the treatment of various diseases, such as cancer, cardiovascular disease, and infectious diseases. Some naphthoquinones, such as plumbagin and lawsone, have shown promising results in preclinical studies and are being investigated for their therapeutic potential. However, more research is needed to fully understand the safety and efficacy of naphthoquinones as a treatment for human diseases.

Proguanil is an antimalarial medication that is used to prevent and treat certain types of malaria. It works by inhibiting the growth and reproduction of the Plasmodium parasite, which causes malaria. Proguanil is typically taken as a pill and is often used in combination with other antimalarial medications to increase its effectiveness. It is usually prescribed for travelers to areas where malaria is common, as well as for people who are at high risk of contracting the disease due to their occupation or health status.

Sulfadiazine is an antibiotic medication that is used to treat a variety of bacterial infections, including urinary tract infections, skin infections, and respiratory infections. It works by inhibiting the growth and reproduction of bacteria in the body. Sulfadiazine is typically administered orally in the form of tablets or capsules. It may also be available as a liquid or as a cream or ointment for topical use. It is important to note that sulfadiazine is not effective against viral infections, such as the flu or common cold. It is also not recommended for use in pregnant women or children under the age of 12, as it may cause harm to these populations. Side effects of sulfadiazine may include nausea, vomiting, diarrhea, headache, and skin rash. In rare cases, it may cause more serious side effects, such as liver damage or blood disorders. It is important to follow the instructions of your healthcare provider and to report any side effects to them immediately.

Cytochromes b are a group of heme-containing proteins that are involved in the electron transport chain in mitochondria. They are part of the respiratory chain, which is responsible for generating energy in the form of ATP from glucose and other nutrients. In the medical field, cytochromes b are important because they play a crucial role in the production of energy in cells. Mutations in the genes that encode for cytochromes b can lead to a variety of diseases, including mitochondrial disorders, which can cause a range of symptoms such as muscle weakness, fatigue, and neurological problems. Cytochromes b are also important in the field of cancer research, as they are involved in the metabolism of cancer cells. By understanding how cytochromes b function in cancer cells, researchers may be able to develop new treatments for cancer.

Antimalarials are a class of drugs used to prevent and treat malaria, a life-threatening disease caused by Plasmodium parasites. These drugs work by inhibiting the growth and reproduction of the parasites within red blood cells, thereby reducing the severity and duration of the disease. There are several types of antimalarials, including: 1. Chloroquine: This is one of the oldest and most widely used antimalarials. It works by inhibiting the ability of the parasite to digest hemoglobin, a protein found in red blood cells. 2. Amodiaquine: This drug is similar to chloroquine and is often used in combination with other antimalarials. 3. Quinine: This is an older antimalarial that is still used in some parts of the world. It works by interfering with the parasite's ability to reproduce. 4. Artemisinin-based combination therapies (ACTs): These are the most effective antimalarials currently available. They combine an artemisinin derivative with another antimalarial drug to increase their effectiveness and reduce the risk of resistance. Antimalarials are typically taken orally, although some are administered intravenously in severe cases. It is important to take antimalarials as directed by a healthcare provider to ensure their effectiveness and reduce the risk of resistance.

Propyl gallate is a food additive and preservative that is commonly used to prevent the oxidation of fats and oils in food products. It is also used in cosmetics and pharmaceuticals as a preservative and antioxidant. In the medical field, propyl gallate is not typically used as a treatment for any specific condition, but it may be used in some research studies as a tool to investigate the effects of antioxidants on various biological processes. It is important to note that propyl gallate is considered safe for consumption in small amounts, but larger doses may cause side effects such as nausea, vomiting, and diarrhea.

Pneumonia, Pneumocystis is a type of pneumonia caused by the Pneumocystis jirovecii fungus. It is a common infection in people with weakened immune systems, such as those with HIV/AIDS, organ transplant recipients, and patients undergoing chemotherapy or radiation therapy. The symptoms of Pneumocystis pneumonia can include fever, cough, shortness of breath, chest pain, and fatigue. In severe cases, it can lead to respiratory failure and death if left untreated. Diagnosis of Pneumocystis pneumonia typically involves a combination of chest X-rays, blood tests, and microscopic examination of sputum or bronchoalveolar lavage fluid. Treatment typically involves the use of antifungal medications, such as trimethoprim-sulfamethoxazole or pentamidine.

In the medical field, a suspension is a type of medication that is administered as a liquid or powder that is suspended in a liquid. Suspensions are typically used when a medication needs to be given in a form that is not available as a tablet, capsule, or other solid form. Suspensions can be made from a variety of ingredients, including active pharmaceutical ingredients (APIs), excipients, and stabilizers. APIs are the active ingredients that provide the therapeutic effect of the medication, while excipients are substances that help to improve the stability, texture, or taste of the suspension. Stabilizers are added to prevent the API from settling out of the suspension and to ensure that the suspension remains homogeneous. Suspensions are commonly used to deliver medications to children, as well as to patients who have difficulty swallowing solid forms of medication. They can also be used to deliver medications that are not available in solid form, such as certain vaccines or antiviral medications. It is important to note that suspensions can be more prone to contamination and degradation than solid forms of medication, so they must be stored and handled properly to maintain their effectiveness and safety.

Trimethoprim-Sulfamethoxazole Combination is a medication that contains two antibiotics: trimethoprim and sulfamethoxazole. It is commonly used to treat bacterial infections such as urinary tract infections, respiratory tract infections, and skin infections. The combination of these two antibiotics provides a broad spectrum of coverage against a variety of bacteria. Trimethoprim inhibits bacterial dihydrofolate reductase, while sulfamethoxazole inhibits bacterial dihydropteroate synthase, both of which are essential for bacterial growth and replication. The medication is usually taken orally in tablet form and is generally well-tolerated, although it may cause side effects such as nausea, vomiting, and allergic reactions.

Coccidiostats are a class of drugs used in veterinary medicine to prevent or treat coccidiosis, a parasitic infection caused by protozoan parasites of the genus Eimeria. Coccidiostats work by inhibiting the growth and reproduction of the parasites, thereby reducing the severity of the infection. There are several types of coccidiostats, including sulfa drugs, synthetic chemicals, and ionophores. Some common examples of coccidiostats include sulfadimethoxine, monensin, and lasalocid. Coccidiostats are typically used in livestock, such as chickens, turkeys, and pigs, to prevent or treat coccidiosis, which can cause significant economic losses due to reduced growth rates, poor feed conversion, and increased mortality. However, the use of coccidiostats can also lead to the development of drug-resistant strains of the parasite, which can make treatment more difficult. Therefore, the use of coccidiostats is often regulated by government agencies to ensure their safe and effective use.

Toxoplasmosis, cerebral refers to an infection of the brain caused by the protozoan parasite Toxoplasma gondii. The parasite can infect people and animals, and it is commonly found in cats. When the parasite infects the brain, it can cause inflammation and damage to brain tissue, leading to a range of symptoms such as headaches, fever, confusion, seizures, and changes in behavior or personality. In severe cases, cerebral toxoplasmosis can be life-threatening. It is typically diagnosed through blood tests or imaging studies such as MRI or CT scans. Treatment may involve antiparasitic medications to kill the parasite and reduce inflammation in the brain.

Malaria, Falciparum is a type of malaria caused by the Plasmodium falciparum parasite. It is the most deadly form of malaria, accounting for the majority of malaria-related deaths worldwide. The parasite is transmitted to humans through the bite of infected female Anopheles mosquitoes. Symptoms of falciparum malaria can include fever, chills, headache, muscle and joint pain, nausea, vomiting, and fatigue. In severe cases, the disease can lead to organ failure, coma, and death. Falciparum malaria is typically treated with antimalarial drugs, such as artemisinin-based combination therapies (ACTs). Prevention measures include the use of insecticide-treated bed nets, indoor residual spraying, and antimalarial prophylaxis for travelers to high-risk areas.

Electron Transport Complex III, also known as cytochrome bc1 complex, is a large protein complex located in the inner mitochondrial membrane. It is a key component of the electron transport chain, which is responsible for generating ATP (adenosine triphosphate) through oxidative phosphorylation. In the electron transport chain, electrons are transferred from one molecule to another through a series of redox reactions. Complex III accepts electrons from the mobile electron carrier molecule ubiquinone (CoQ) and passes them on to the next complex in the chain. As electrons are passed along, energy is harnessed to pump protons across the inner mitochondrial membrane, creating a proton gradient that drives ATP synthesis. Complex III also plays a role in the production of reactive oxygen species (ROS), which can damage cellular components and contribute to aging and disease. However, the complex is also equipped with mechanisms to protect against ROS damage, making it an important target for research in the field of aging and disease prevention.

Dapsone is a medication that is used to treat a variety of infections, including leprosy, dermatitis herpetiformis, and certain types of pneumonia. It is also used to treat certain types of parasitic infections, such as babesiosis and trypanosomiasis. Dapsone works by inhibiting the production of folic acid, which is essential for the growth and reproduction of bacteria and parasites. It is usually taken by mouth, although it can also be given intravenously or topically. Side effects of dapsone may include nausea, vomiting, headache, and anemia. It is important to note that dapsone can cause a severe reaction called Steven-Johnson syndrome, which can be life-threatening. Therefore, it should only be used under the supervision of a healthcare professional.

Antifungal agents are medications used to treat fungal infections. These infections can affect various parts of the body, including the skin, nails, hair, respiratory system, and gastrointestinal tract. Antifungal agents work by inhibiting the growth and reproduction of fungi, either by disrupting their cell walls or by interfering with their metabolism. There are several types of antifungal agents, including: 1. Azoles: These are the most commonly used antifungal agents and include fluconazole, itraconazole, and voriconazole. They work by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes. 2. Polyenes: These include amphotericin B and nystatin and work by disrupting the fungal cell membrane. 3. Echinocandins: These include caspofungin, micafungin, and anidulafungin and work by inhibiting the synthesis of β-1,3-glucan, a component of the fungal cell wall. 4. Allylamines: This includes terbinafine and works by inhibiting the synthesis of squalene, a precursor to ergosterol. Antifungal agents are typically prescribed based on the type of fungal infection, the severity of the infection, and the patient's overall health. It is important to follow the prescribed dosage and duration of treatment to ensure effective treatment and prevent the development of drug-resistant fungal strains.

... is a hydroxy-1,4-naphthoquinone, an analog of both ubiquinone and lawsone. Atovaquone is a medication used to treat ... "Atovaquone Oral SUSPENSION- atovaquone suspension". DailyMed. 10 December 2019. Retrieved 18 September 2020. Hughes W, Leoung G ... Preliminary research found that atovaquone could inhibit the replication of SARS-CoV-2 in vitro. Clinical trials of atovaquone ... Wikimedia Commons has media related to Atovaquone. "Atovaquone". Drug Information Portal. U.S. National Library of Medicine. ...
Atovaquone (PCP/Malaria); Exosurf (infant respiratory distress); Mivacron and Nuromax (neuromuscular blockade); Wellferon ( ...
The addition of proguanil has shown to reduce resistance to atovaquone and increase the ability of atovaquone to trigger a ... "Atovaquone And Proguanil (Oral Route) Side Effects". Mayo Clinic. Archived from the original on 2016-11-09. Retrieved 2016-11- ... "Atovaquone and Proguanil Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 20 ... In the United States and Canada it is only available in combination as atovaquone/proguanil. When the Japanese attack on Pearl ...
Other options include pentamidine, dapsone and atovaquone. It is fatal in 10-20% of people with HIV/AIDS. Pneumocystosis in ...
... atovaquone). Also propylhexedrine inhibits cytochrome c reductase. A small fraction of electrons leave the electron transport ...
... or the combination of atovaquone/proguanil (Malarone)-are frequently used for prevention. Doxycycline and the atovaquone/ ... Atovaquone-proguanil is effective against uncomplicated falciparum with a possible failure rate of 5% to 10%; the addition of ... Blanshard A, Hine P (January 2021). "Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria". The ... except for atovaquone/proguanil, which only needs to be started two days before and continued for seven days afterward). The ...
November 2000). "Atovaquone and azithromycin for the treatment of babesiosis". N. Engl. J. Med. 343 (20): 1454-1458. doi: ... treatment regimens have been increasingly leaning towards oral atovaquone with oral azithromycin. The latter are preferred, as ...
... is a naphthoquinone antiprotozoal drug related to atovaquone. It is a promising compound for the therapy and ... Its mode of action is thus likely to be similar to that of the antimalarial drug atovaquone, a similar 2-hydroxy-1,4- ...
Doxycycline and atovaquone/proguanil provide protection within one to two days and may be better tolerated. If a person becomes ... October 2001). "Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a ... In the mefloquine arm, 5% of the users reported severe events requiring medical attention, versus 1.2% in the atovaquone- ... Prophylaxis with mefloquine was compared to prophylaxis with atovaquone-proguanil. Roughly 67% of participants in the ...
Anina D. Murphy & Naomi Lang-Unnasch (1999). "Alternative Oxidase Inhibitors Potentiate the Activity of Atovaquone against ...
However, more recent work has indicated that, while proguanil is synergistic with the drug atovaquone (as in the combination ... Thapar MM, Gupta S, Spindler C, Wernsdorfer WH, Björkman A (May 2003). "Pharmacodynamic interactions among atovaquone, ... "A mechanism for the synergistic antimalarial action of atovaquone and proguanil". Antimicrobial Agents and Chemotherapy. 43 (6 ... Malarone), cycloguanil is in fact antagonistic to the effects of atovaquone, suggesting that, unlike cycloguanil, proguanil may ...
Atovaquone is recommended to be used only in combination with another anti-malarial compound as the selection of resistant ... A liquid oral suspension of Atovaquone is available under the name Mepron. Primaquine is a highly active 8-aminoquinolone that ... However it is useful in prophylaxis when combined with atovaquone or chloroquine (in areas where there is no chloroquine ... Atovaquone is available in combination with proguanil under the name Malarone, albeit at a price higher than Lariam. It is ...
Antiparasitics that have been investigated include chloroquine, hydroxychloroquine, mefloquine, ivermectin, and atovaquone. ...
Atovaquone-proguanil is an effective alternative in patients unable to tolerate chloroquine. Quinine may be used to treat vivax ... "Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand". ...
Cohn, L.A.; Birkenheuer, A.J.; Brunker J.D.; Ratcliff E.R.; Craig, A.W. (2011). "Efficacy of Atovaquone and Azithromycin or ... Cohn, L.A.; Birkenheuer, A.J.; Brunker, J.D.; Ratcliff, E.R.; Craig, A.W. (2011). "Efficacy of Atovaquone and Azithromycin or ... 60% of sick cats treated with supportive care and the combination of the anti-malarial drug atovaquone and the antibiotic ... The most often used treatments for cytauxzoonosis are imidocarb dipropionate and a combination of atovaquone and azithromycin. ...
Lell B, Luckner D, Ndjavé M, Scott T, Kremsner PG (March 1998). "Randomised placebo-controlled study of atovaquone plus ... He has been principal investigator on key studies for the development of atovaquone/proguanil, artesunate/amodiaquine, ...
Mefloquine, doxycycline, and atovaquone-proguanil appear to be equally effective at reducing the risk of malaria for short-term ... Mefloquine (Lariam), doxycycline, or the combination of atovaquone and proguanil (Malarone) are frequently recommended. In ... atovaquone/proguanil (Malarone) 1 tablet daily (started one day before travel, and continued for one week after returning). Can ... however mefloquine is not always as well tolerated when compared with atovaquone-proguanil. There is low-quality evidence ...
The combination atovaquone-proguanil may be used in those patients who are unable to take chloroquine for whatever reason. An ... Radloff PD, Philipps J, Hutchinson D, Kremsner PG (1996). "Atovaquone plus proguanil is an effective treatment for Plasmodium ...
In mild-to-moderate babesiosis, the treatment of choice is a combination of atovaquone and azithromycin. This regimen is ...
International travelers to endemic zones are advised chemoprophylaxis with antimalarial drugs like Atovaquone-proguanil, ...
In areas where resistance is present, other antimalarials, such as mefloquine or atovaquone, may be used instead. The Centers ...
The medications prescribed for latent toxoplasmosis are: Atovaquone - an antibiotic that has been used to kill Toxoplasma cysts ... Djurković-Djaković O, Milenković V, Nikolić A, Bobić B, Grujić J (2002). "Efficacy of atovaquone combined with clindamycin ... inside AIDS patients Clindamycin - an antibiotic that, in combination with atovaquone, seemed to optimally kill cysts in mice ...
For travellers returning to nonendemic countries, atovaquone/proguanil, artemether/lumefantrineany and quinine plus doxycycline ...
Other medications that are used, alone or in combination, include pentamidine, trimetrexate, dapsone, atovaquone, primaquine, ... atovaquone, or regular pentamidine inhalations may help prevent PCP. Antipneumocystic medication is used with concomitant ...
... proguanil with atovaquone), are often used when oral therapy is required. Quinine ethyl carbonate is tasteless and odourless, ...
Malarone (a combination of atovaquone and proguanil) seldom has side effects, but headache, nausea, vomiting and abdominal pain ...
"Mutation underlying resistance of Plasmodium berghei to atovaquone in the quinone binding domain 2 (Qo(2)) of the cytochrome b ... berghei are associated with resistance to the anti-malarial drug atovaquone. Human genes encoding cytochrome b proteins include ...
Some of these inhibitors, such as lonidamine and atovaquone, which inhibit Complex II and Complex III, respectively, are ...
... and atovaquone. Mitochondria that lack their own DNA have been found in a marine parasitic dinoflagellate from the genus ...
The institute's achievements include contributions to the development of malaria drugs, such as atovaquone-proguanil, ...
Atovaquone is a hydroxy-1,4-naphthoquinone, an analog of both ubiquinone and lawsone. Atovaquone is a medication used to treat ... "Atovaquone Oral SUSPENSION- atovaquone suspension". DailyMed. 10 December 2019. Retrieved 18 September 2020. Hughes W, Leoung G ... Preliminary research found that atovaquone could inhibit the replication of SARS-CoV-2 in vitro. Clinical trials of atovaquone ... Wikimedia Commons has media related to Atovaquone. "Atovaquone". Drug Information Portal. U.S. National Library of Medicine. ...
Atovaquone: learn about side effects, dosage, special precautions, and more on MedlinePlus ... When atovaquone is used to treat pneumonia, it is usually taken with meals twice a day for 21 days. When atovaquone is used to ... Before taking atovaquone,. *tell your doctor and pharmacist if you are allergic to atovaquone, any other medications, or any of ... Take atovaquone exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. ...
Atovaquone reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI). ... Detailed Atovaquone dosage information Cautions for Atovaquone. Contraindications. * Hypersensitivity to atovaquone or any ... Atovaquone in conjunction with pyrimethamine (and leucovorin), atovaquone in conjunction with sulfadiazine, or atovaquone alone ... Atovaquone drug interactions (more detail). Atovaquone Pharmacokinetics. Absorption. Bioavailability. Following oral ...
Atovaquone and Proguanil The combination of atovaquone and proguanil is used to treat a certain kind of malaria infection (a ... Atovaquone Atovaquone is used to treat Pneumocystis jiroveci [Pneumocystis carinii] pneumonia (PCP; type of pneumonia most ... Other medicines that are sometimes used include: Atovaquone Paromomycin These medicines often help only for a ... ... include: Artemisinin derivative combinations, including artemether and lumefantrine Atovaquone-proguanil Quinine-based regimen ...
Legrand E, Demar M, Volney B, Ekala MT, Quinternet M, Bouchier C, First case of emergence of atovaquone resistance in ... Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Mühlen M, Screening for mutations related to atovaquone/ ... Atovaquone/proguanil resistance in Africa: a case report. Scand J Infect Dis. 2003;35:898. DOIPubMedGoogle Scholar ... Apparently correct initial atovaquone concentration on day 3 did not predict the outcome of treatment because A-P acts slowly, ...
... and atovaquone plus proguanil in travelers from Denmark. Download Prime PubMed App to iPhone, iPad, or Android ... Atovaquone + proguanil: new preparation. Second-line antimalarial combination.. *Atovaquone-proguanil (malarone): an effective ... AfricaAntimalarialsAsiaAtovaquoneCase-Control StudiesChloroquineDenmarkDisease OutbreaksDrug Therapy, CombinationHumans ... Atovaquone/proguanil (Malarone) was at least as efficient as mefloquine, but breakthroughs were observed. SN - 1195-1982 UR - ...
Atovaquone. Note on Treatment in Pregnancy Atovaquone is in pregnancy category C. Data on the use of atovaquone in pregnant ... It is not known whether atovaquone is excreted in breast milk. Atovaquone should be used with caution in women breastfeeding ... Atovaquone PLUS azithromycin; OR. *Clindamycin PLUS quinine (this combination is the standard of care for severely ill patients ... Anecdotal cases of babesiosis in children, including infants, have been safely treated with azithromycin plus atovaquone. ...
We have manufactured of ATOVAQUONE IMPURITIES Impurity. It is fully characterized using HPLC, LC-MS, 1H NMR spectra and COA and ... Rxn Chemicals is manufacturer and supplier of unknown Impurity of ATOVAQUONE IMPURITIES impurity which can be used for ANDA ... We also perform custom synthesis and purification of ATOVAQUONE IMPURITIES impurity from mg to gm scale.. ...
Reply To: artemether/atovaquone/doxycycline combo. Introduction to Protomyxzoa › Forums › Protomyxzoa Discussion › artemether/ ... Attached to this thread is a paper on synergism between atovaquone and artemisinin. I just found it a few days ago. ... Preliminary results are in: atovaquone (in the form of mepron) + artemisinin/artemether + doxycycline (AAD protocol) is THE ... In treating malaria, there is evidence that artemisinin/artemether, atovaquone and doxycyclines are all synergistic with each ...
is your trusted source for Atovaquone Proguanil tablets malaria ...
Retrieved from "https://hemonc.org/w/index.php?title=Atovaquone_(Mepron)&oldid=71601" ...
For atovaquone, the dosage is 1500 mg by mouth once daily given with food. This agent has a low toxicity profile and is an ... Atovaquone 750 mg by mouth twice daily may be given as an alternative treatment, but its use is contraindicated in pregnancy. ... In patients who cannot tolerate TMP-SMX, other options include dapsone, dapsone plus pyrimethamine, atovaquone, and aerosolized ... What is the chemoprophylactic regimen for atovaquone in reference to Pneumocystis jiroveci pneumonia (PJP)? ...
... is voluntarily recalling two lots of Atovaquone Oral Suspension, USP 750 mg/5mLto the consumer level. The recall is based on ... KVK Tech Inc., Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750 mg/5mL Due to Temperature Abuse August ... KVK Tech, Inc., is voluntarily recalling two lots of Atovaquone Oral Suspension, USP 750 mg/5mLto the consumer level. The ... Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750 mg/5mL Due to Temperature Abuse. ...
Mefloquine was the most commonly used drug for treatment until the early 2010s; atovaquone/proguanil was the most commonly used ... atovaquone/proguanil, and mefloquine). A/L = artemether/lumefantrine; A/P = atovaquone/proguanil; IV = intravenous; PR = per ... atovaquone/proguanil, and mefloquine). A/L = artemether/lumefantrine; A/P = atovaquone/proguanil; IV = intravenous; PR = per ... atovaquone/proguanil, and mefloquine). A/L = artemether/lumefantrine; A/P = atovaquone/proguanil; IV = intravenous; PR = per ...
Atovaquone-proguanil (Malarone®) is another recommended option. P. vivax infections acquired from regions other than Papua New ...
Atovaquone 750 mg every 12 h with food. Zidovudine 200 mg every 8 h. 14. ↑31%. Range: 23% to 78%c. ↔. ...
Atovaquone. Date of publication: 01/10/2015. *Atracurium. Date of publication: 27/10/2017 ...
Atovaquone. *Nitrofurans. *Erythromycin. Learn more about antibiotic treatment by downloading Deutsche Borreliose- ...
Atovaquone (ATQ). Novartis internal chemical library. Synthesized by Novartis. Chemical compound, drug. Tafenoquine (TQ). ... Reference antimalarials which included non anti-relapsing compounds such as atovaquone (ATQ) (0.25 µM) and KDU691 (0.5 µM); the ... resistance to atovaquone (ATQ) (Baggish and Hill, 2002) and PI4K inhibitors (Zeeman et al., 2014; Zeeman et al., 2016). We thus ... namely that they are susceptible to 8-aminoquinolines but phenotypically resistant to atovaquone and PI4K inhibitors. ...
... such as azithromycin and atovaquone (2). ...
... trimethoprim/sulfamethoxazole or atovaquone (Mepron) offers sufficient prophylaxis against both. Primary prophylaxis against ...
Information provided on this site is intended for use only by residents of the United States. The products discussed herein are available only upon prescription from a medical doctor or a qualified medical professional. Consumers should not construe any information herein as medical advice or as a substitute for discussions with a prescribing practitioner or other qualified medical professional. Reader understands and agrees to the foregoing. ...
Malarone (Atovaquone + Proguanil HCL). Anti-Neoplastic Agents - Purinethol (Marcaptopurine and Gleevec (Imatinib Mesylate) are ...
Atovaquone. September 14, 2010 ARC (Zinc Oxide Topical). September 9, 2010 Aldoril 15 (Hydrochlorothiazide Methyldopa). August ...
atovaquone. Minor (1)tetracycline decreases levels of atovaquone by inhibition of GI absorption. Applies only to oral form of ... atovaquone. tetracycline decreases levels of atovaquone by inhibition of GI absorption. Applies only to oral form of both ...
Toxoplasmosis may respond to other antimicrobials, including macrolide antibiotics, dapsone, clinidamycin, and atovaquone. ...
  • Fewer than 25 cases of falciparum malaria that failed to respond to atovaquone-proguanil (A-P) have been noted in published articles since the 1996 registration of Malarone (GlaxoSmithKline, Marly-le-Roi, France) ( 1 , 2 ). (cdc.gov)
  • each tablet contains 250 mg of atovaquone and 100 mg of proguanil hydrochloride). (cdc.gov)
  • Two hundred cases of Plasmodium falciparum malaria were notified of which 103 had used chloroquine and proguanil, 16 mefloquine, and 3 atovaquone and proguanil as prophylaxis, whereas the rest had taken other drugs or no prophylaxis. (unboundmedicine.com)
  • The study provided the first comprehensive data on the use of atovaquone/proguanil to travelers. (unboundmedicine.com)
  • Atovaquone/proguanil (Malarone) was at least as efficient as mefloquine, but breakthroughs were observed. (unboundmedicine.com)
  • Atovaquone Proguanil tablets malaria. (medicomart.com)
  • Number of malaria cases treated at the National Center for Global Health and Medicine, by the antimalarial regimen used (quinine, artesunate, artemether/lumefantrine, atovaquone/proguanil, and mefloquine). (ajtmh.org)
  • Drugs of choice are: atovaquone proguanil, doxycycline, and mefloquine. (jeancoutu.com)
  • Malaria Cases in ease and was treated with a combination of oral atovaquone and proguanil. (cdc.gov)
  • Preliminary results are in: atovaquone (in the form of mepron) + artemisinin/artemether + doxycycline (AAD protocol) is THE most effective combination I have tried. (protomyxzoa.org)
  • Babesiosis can be treated using a combination of antimicrobial medications, such as azithromycin and atovaquone ( 2 ). (cdc.gov)
  • In treating malaria, there is evidence that artemisinin/artemether, atovaquone and doxycyclines are all synergistic with each other. (protomyxzoa.org)
  • Atovaquone is in a class of medications called antiprotozoal agents. (medlineplus.gov)
  • Atovaquone is also sometimes used along with other medications to treat babesiosis (an infectious disease carried by ticks). (medlineplus.gov)
  • tell your doctor and pharmacist if you are allergic to atovaquone, any other medications, or any of the ingredients in atovaquone suspension. (medlineplus.gov)
  • Because data are available about safe administration of quinine plus clindamycin during pregnancy, this drug combination, rather than atovaquone (plus azithromycin), generally is recommended for treatment of symptomatic babesiosis during pregnancy, unless the preferred medications are not available or tolerated. (cdc.gov)
  • Attached to this thread is a paper on synergism between atovaquone and artemisinin. (protomyxzoa.org)
  • KVK Tech, Inc., is voluntarily recalling two lots of Atovaquone Oral Suspension, USP 750 mg/5mLto the consumer level. (clgtrial.com)
  • Atovaquone comes as a suspension (liquid) to take by mouth. (medlineplus.gov)
  • Atovaquone in conjunction with pyrimethamine (and leucovorin), atovaquone in conjunction with sulfadiazine, or atovaquone alone are alternative regimens for treatment of toxoplasmosis † [off-label] in HIV-infected adults and adolescents when regimen of choice and preferred alternative cannot be used. (drugs.com)
  • If you stop taking atovaquone too soon or skip doses, your infection may not be completely treated or you may not be protected from future infections. (medlineplus.gov)
  • If you become pregnant while taking atovaquone, call your doctor. (medlineplus.gov)
  • Atovaquone is in pregnancy category C. Data on the use of atovaquone in pregnant women are limited, and the risk to the embryo-fetus is unknown. (cdc.gov)
  • When atovaquone is used to treat pneumonia, it is usually taken with meals twice a day for 21 days. (medlineplus.gov)
  • Atovaquone will not treat these infections. (medlineplus.gov)
  • Atovaquone is also used to prevent PCP in teenagers and adults who cannot take another medication used for prevention. (medlineplus.gov)
  • Atovaquone used alone is one of several alternatives recommended by CDC, NIH, and IDSA for treatment of mild to moderate PCP in HIV-infected adults and adolescents when co-trimoxazole cannot be used. (drugs.com)
  • When atovaquone is used to prevent pneumonia, it is usually taken with a meal once a day. (medlineplus.gov)
  • High-performance liquid chromatography on day 3 of treatment (performed 20 h after the last drug intake) showed an atovaquone plasma concentration of 3.1 μg/mL. (cdc.gov)
  • Although efficacy and safety not established in pediatric patients and data limited regarding use in children, CDC, NIH, IDSA, and AAP state atovaquone also can be considered an alternative for treatment of mild to moderate PCP in HIV-infected children † [off-label] when co-trimoxazole cannot be used. (drugs.com)
  • The antimalarial drug atovaquone was recently reported to inhibit the in vitro replication of different arboviruses , including chikungunya virus (CHIKV) and Zika virus ( ZIKV ). (bvsalud.org)
  • Furthermore, atovaquone was shown to block Plasmodium parasite transmission by Anopheles mosquitoes when the mosquitoes were exposed to low concentrations on treated surfaces (i.e. tarsal exposure). (bvsalud.org)
  • Because data are available about safe administration of quinine plus clindamycin during pregnancy, this drug combination, rather than atovaquone (plus azithromycin), generally is recommended for treatment of symptomatic babesiosis during pregnancy, unless the preferred medications are not available or tolerated. (cdc.gov)
  • Atovaquone therapy is associated with low rates of serum enzyme elevations and has been linked to only rare cases of clinically apparent liver injury. (nih.gov)
  • The severity of hepatic injury due to atovaquone varies from mild serum enzyme elevations that are asymptomatic and transient, to clinically apparent liver injury with jaundice. (nih.gov)
  • The mean AUC of atovaquone suspension in serum after concomitant administration with an enteral nutrient supplement (Sustacal Plus) was significantly greater than the mean AUC found with fasting. (medscape.com)
  • There have also been rare reports of clinically apparent, acute liver injury due to atovaquone. (nih.gov)
  • Atovaquone (a toe' va kwone) is a synthetic naphthoquinone that acts by interfering with mitochondrial electron transport in susceptible organisms. (nih.gov)
  • Atovaquone is available in tablets of 250 and 500 mg and as a suspension of 750 mg/5 mL under the brand name Mepron. (nih.gov)
  • When atovaquone is used to treat pneumonia, it is usually taken with meals twice a day for 21 days. (medlineplus.gov)
  • When atovaquone is used to prevent pneumonia, it is usually taken with a meal once a day. (medlineplus.gov)
  • Monitor for reduced therapeutic effect of atovaquone. (medscape.com)
  • Therapeutic plasma concentrations may not be achieved if atovaquone is administered during fasting. (medscape.com)
  • Atovaquone has also been linked to rare instances of Stevens Johnson syndrome, which is frequently accompanied by mild liver injury or liver enzyme elevations. (nih.gov)
  • The mechanism by which atovaquone might cause liver injury is unknown. (nih.gov)
  • Atovaquone is in pregnancy category C. Data on the use of atovaquone in pregnant women are limited, and the risk to the embryo-fetus is unknown. (cdc.gov)
  • Atovaquone (ATQ) exerts its action by inhibiting plasmodial mitochondria electron transport at the level of the cytochrome bc1 complex. (unl.pt)
  • The recommended dosage of atovaquone varies by different indications. (nih.gov)
  • Acute liver failure , chronic hepatitis and vanishing bile duct syndrome have not been reported after atovaquone therapy. (nih.gov)
  • Metoclopramide may decrease the absorption of atovaquone. (medscape.com)
  • metoclopramide decreases levels of atovaquone by inhibition of GI absorption. (medscape.com)
  • Therefore, atovaquone should be administered with enteral nutrition for maximal absorption (grade 1A). (medscape.com)
  • Well-documented cases that were not attributed to suboptimal dosage or impaired bioavailability essentially due to vomiting, diarrhea, or both, showed atovaquone-resistant parasites in the recrudescent isolate, with Y268S or Y268N cytochrome b mutations ( 2 - 10 ). (cdc.gov)
  • efavirenz decreases levels of atovaquone by unspecified interaction mechanism. (medscape.com)
  • indinavir will decrease the level or effect of atovaquone by unknown mechanism. (medscape.com)
  • atovaquone increases effects of warfarin by unspecified interaction mechanism. (medscape.com)
  • Monitor Closely (1) indinavir will decrease the level or effect of atovaquone by unknown mechanism. (medscape.com)
  • We first confirmed that atovaquone exerted a dose -dependent antiviral effect on CHIKV and ZIKV replication in mosquito -derived cells . (bvsalud.org)
  • High-performance liquid chromatography on day 3 of treatment (performed 20 h after the last drug intake) showed an atovaquone plasma concentration of 3.1 μg/mL. (cdc.gov)
  • If you stop taking atovaquone too soon or skip doses, your infection may not be completely treated or you may not be protected from future infections. (medlineplus.gov)
  • Atovaquone did not significantly reduce ZIKV or CHIKV infection in Ae. (bvsalud.org)
  • Atovaquone may cause side effects. (medlineplus.gov)
  • Therefore, we evaluated the anti-CHIKV and - ZIKV effects of atovaquone via tarsal exposure in Aedes aegypti mosquitoes . (bvsalud.org)
  • metoclopramide intranasal will increase the level or effect of atovaquone by Other (see comment). (medscape.com)
  • Monitor Closely (1) metoclopramide intranasal will increase the level or effect of atovaquone by Other (see comment). (medscape.com)
  • Next, we assessed the effect of tarsal exposure to atovaquone on the fitness of Ae. (bvsalud.org)
  • To evaluate the antiviral effect of atovaquone against CHIKV, we exposed female mosquitoes to 100 µmol/m2 atovaquone for 1h, after which the mosquitoes were immediately infected with CHIKV or ZIKV via bloodmeal. (bvsalud.org)